RxDoctor Payments Data

Benahili Iboaya, DO

Nephrology · Findlay, OHNPI 1699755876

Payments from drug & device makers

$1,615in general payments, 2019–2025

Across 63 payments — averaging $25.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$387
  • Outset Medical Inc$246
  • Vifor Pharma, Inc.$245
  • Novo Nordisk$116
  • Amgen$114
  • Otsuka America Pharmaceutical, Inc.$102
  • plus $405 from 11 others

What the payments were for

  • Food & beverage$1,12870%
  • Education$48830%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,615 in reported general payments places this provider in the 55th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio

Medicare billing

Part B allowed, 2024
$942,254
Medicare patients
1,080
Services billed
6,641

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide14$40,409
Sevelamer Carbonate131$32,478
LokelmaSodium Zirconium Cyclosilicate35$22,022
JardianceEmpagliflozin35$21,103
FarxigaDapagliflozin Propanediol30$20,877
Bumetanide236$13,477
Midodrine Hcl175$8,656
Calcium Acetate146$8,070
Cinacalcet Hcl41$7,718
Potassium Citrate ErPotassium Citrate36$6,537
Lanthanum Carbonate13$6,515
SpsSodium Polystyrene Sulfon/Sorb37$5,808
Calcitriol388$4,927
Nifedipine ErNifedipine138$2,817
Allopurinol290$2,237

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma, Farxiga$387$42,89965 claims
Fresenius USA Marketing, Inc.Velphoro$49$40,40914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 450 nephrology providers in Ohio.

Other nephrology in Findlay

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →